Celebrex (Celecoxib) Treatment of Laryngeal Papilloma
Stopped: 03/01/2009,due to date close to termination of this funding/study period
United States10 participantsStarted 2005-05
Plain-language summary
Respiratory recurrent papilloma (RRP) is one of the most common benign tumors. Surgical removal is the current management for RRP, but it is a very traumatic procedure, and often leads to permanent voice dysfunction. In this study, we will develop a new, combined RRP treatment with a pulsed dye laser (PDL) and Celebrex. We will determine if Celebrex, a newly developed inhibitor of cyclooxygenase (COX)-2, can provide a long-term inhibitory effect on RRP, therefore preventing RRP from recurring. This combined strategy, if successful in this proposed study, will provide a new and ideal "voice-preserving" therapy for RRP that will deliver long-term efficacy in managing RRP.
Who can participate
Age range18 Years – 64 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. 18 to 64 years of age
✓. with laryngeal papillomas requiring surgical treatment
✓. willingness to participate in the study
✓. a signed informed consent form
Exclusion criteria
✕. age less than 18 years
✕. evidence of mental impairment so that the patient can not understand or sign the consent form
✕. malignant diseases such as laryngeal cancer
✕. established coronary heart and artery disorder, cerebrovascular disease, and other cardiovascular diseases
✕. established diabetes, which requires (1) insulin treatment; or (2) more than 2 oral agents of medication; or (3) to have a baseline HgbA1c \>8.0
✕. hypertension, with ongoing blood pressure \> 150 mg Hg systolic or to require medication
What they're measuring
1
Number of Case With Papilloma Recurrence During a 12-month Follow up